LIXTE BIOTECHNOLOGY HOLDINGS, INC. ANNOUNCES THE APPOINTMENT OF REGINA BROWN TO ITS BOARD OF DIRECTORS
12 May 2021 - 11:35PM
Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) today announced
the appointment of Regina Brown, CPA to its board of directors. She
will serve as an independent director and audit committee chair.
Dr. John S. Kovach, Founder and CEO of Lixte,
said “We are pleased to welcome Regina to our board of directors.
We look forward to benefiting from her decades of experience in
public accounting. As our company expands, her expertise in
compliance, taxation and internal control implementation is a
valuable addition to our board of directors.”
Ms. Brown began her accounting practice over 30
years ago. Currently, her practice has a wide range of clients,
varying in size, industry, and geographic locations. They include
large national corporations listed on the New York Stock Exchange,
as well as smaller regional businesses. Other clients consist of
professionals, wholesalers, and high net worth individuals. Many of
her clients have international and cross-border operations.
As a consequence of her depth of experience, she
regularly assists other professionals with their clients’ issues
and performs tax research and analysis in connection with
litigation and other matters including tax and accounting with
respect to mergers and acquisitions and implementation of internal
controls. In addition, international tax matters and compliance
have become a significant part of her practice. She is a member in
good standing of California Society of CPAs and the American
Institute of Certified Public Accountants.
About Lixte
Biotechnology Holdings, Inc.
Lixte Biotechnology Holdings, Inc. (Nasdaq:LIXT)
is a clinical-stage pharmaceutical company dedicated to discovering
drugs for more effective treatments for many forms of cancer and
other serious common diseases. A major driver of cancer is defects
in the switches that turn the biochemical pathways in cells on and
off. Most cancer research over the past 30 years has focused on the
“on” switches because the “off” switches, especially the master
“off” switch protein phosphatase (PP2A), were believed to cause
intolerable toxicity in patients. Lixte has achieved a breakthrough
with its novel, first-in-class lead compound, PP2A inhibitor
LB-100, by demonstrating that it is readily tolerated in cancer
patients at doses associated with anti-cancer activity. This
innovative approach encourages cancer cells, damaged by chemo or
other cancer therapies, to continue to replicate before repairing
the damage, leading to the more efficient death and elimination of
those cells from the body. Lixte has partnered with top
medical institutions and leading academic research centers to
advance the clinical development of its compounds. The LB-100
compound, of which there are no competitors known to Lixte, is
being tested in three clinical cancer treatment studies with others
in planning. lixte.com
Forward-Looking Statements
This announcement contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, and Section 21E of the Securities Exchange
Act of 1934. For example, statements regarding the Company's
financial position, business strategy and other plans and
objectives for future operations, and assumptions and predictions
about future product demand, supply, manufacturing, costs,
marketing and pricing factors are all forward-looking statements.
These statements are generally accompanied by words such as
"intend," anticipate," "believe," "estimate," "potential(ly),"
"continue," "forecast," "predict," "plan," "may," "will," "could,"
"would," "should," "expect" or the negative of such terms or other
comparable terminology. The Company believes that the assumptions
and expectations reflected in such forward-looking statements are
reasonable, based on information available to it on the date
hereof, but the Company cannot provide assurances that these
assumptions and expectations will prove to have been correct or
that the Company will take any action that the Company may
presently be planning. However, these forward-looking statements
are inherently subject to known and unknown risks and
uncertainties. Actual results or experience may differ materially
from those expected or anticipated in the forward-looking
statements. Factors that could cause or contribute to such
differences include, but are not limited to, regulatory policies,
available cash, research results, competition from other similar
businesses, and market and general economic factors. This
discussion should be read in conjunction with the Company's filings
with the United States Securities and Exchange Commission at
sec.gov/edgar.shtml.
Lixte Contact:info@lixte.comGeneral Phone:
(631) 830-7092Investor Phone: (888) 289-5533
Lixte Biotechnology (NASDAQ:LIXT)
Historical Stock Chart
From Apr 2024 to May 2024
Lixte Biotechnology (NASDAQ:LIXT)
Historical Stock Chart
From May 2023 to May 2024